Crosslink Therapeutics Inc.
About Crosslink Therapeutics Inc.
Crosslink Therapeutics Inc. is a Boston-based biotechnology company founded in 2021 that engineers modular biologic domains to conditionally assemble cancer medicines in the tumor microenvironment. The company's technology leverages elevated extracellular ATP levels in solid tumors to improve tumor-specific targeting and activity, and can be adapted across multiple therapeutic modalities including antibody drug conjugates and radioligand therapies. It maintains a website at www.xlinktx.com and focuses on developing first-in-class or best-in-class oncology applications.
- 🔗 Crosslink Therapeutics: Startup Profile and Funding (2026)
- 🔗 Crosslink Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
- 🔗 Crosslink Therapeutics - Cure Ventures
- 🔗 Crosslink Therapeutics - Home
- 🔗 Crossbow Therapeutics Launches with $80 Million in Series A Financing to Advance a Novel Class of Antibody Therapies That Mimic T-Cell Receptors to Treat Cancer - BioSpace
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Raised $5.5M in private placement funding.
- Founded in 2021 and headquartered in Boston, MA.
- Developing conditional assembly technology for tumor-targeted cancer medicines.
- Technology adaptable to antibody drug conjugates and radioligand therapies.
- Website and pipeline details available at xlinktx.com.
Ask StreetZero about Crosslink Therapeutics Inc.
Put our AI to work on this deal.
Similar companies
Other Pharmaceuticals deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account